TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34165523
Drug: Reduced-intensity chemotherapy
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced-intensity chemotherapy with oxaliplatin and capecitabine
Study: 34464489
Drug: Locally applied
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Locally applied vaginal estrogen cream
Study: 32375334
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (70 µg)
Study: 35696838
Drug: Integrated Exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated Exposure Therapy (I‐PE)
Study: 35696838
Drug: Integrated Coping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated Coping Skills Therapy (I‐CS)
Study: 33486855
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg administered immediately after surgery
Study: 33486855
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg administered 30 min before surgery
Study: 33486855
Drug: Postoperative analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative analgesic treatment group
Study: 33486855
Drug: Preoperative analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative analgesic treatment group
Study: 32144336
Drug: SAP P11-4
Normalized name: HURA CREPITANS SAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAP P11-4 and twice fluoride varnish
Study: 32144336
Drug: SAP P11-4
Normalized name: HURA CREPITANS SAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAP P11-4 and twice weekly SAPM (home-application)
Study: 33689786
Drug: Estetrol 15
Normalized name: estetrol
DrugBank: Estetrol (DB12235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Estetrol 15 mg/drospirenone 3 mg (E4/DRSP)
Study: 33689786
Drug: Ethinylestradiol 20
Normalized name: Ethinylestradiol 20 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethinylestradiol 20 µg/drospirenone 3 mg (EE/DRSP)
Study: 36076498
Drug: Puerarin supplementation
Normalized name: Pueraria montana var. chinensis root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Puerarin supplementation (90.2 mg daily)
Study: 33559524
Drug: VX-210 (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: VX-210 (9 mg)
Study: 33415874
Drug: Jin's three-needle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jin's three-needle combined with MyoTrac biostimulation therapy
Study: 33415874
Drug: simple Jin's
Approvals — FDA: no, EMA: no, PMDA: no
Description: simple Jin's three-needle therapy
Study: 33415874
Drug: simple MyoTrac
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: simple MyoTrac biostimulation therapy
Study: 34032997
Drug: SARS-CoV-2 antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV-2 antibodies detection using FDA approved ROCHE kit
Study: 34504990
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy plus ribociclib
Study: 35691448
Drug: Local consolidative
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local consolidative therapy (LCT) plus standard-of-care systemic therapy or observation
Study: 33773533
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (counselling, intra oral camera assessment, and carbon monoxide monitoring)
Study: 33773533
Drug: Counselling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counselling and intra oral camera assessment
Study: 36133438
Drug: Periocline-assisted periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Periocline-assisted periodontal basic therapy
Study: 36133438
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (periodontal basic therapy without periocline)
Study: 33060258
Drug: Aerosolized calfactant
Normalized name: Calfactant
DrugBank: Calfactant (DB06415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerosolized calfactant (Infasurf), 6 mL/kg (210 mg phospholipid/kg body weight), up to 3 treatments, at least 4 hours apart.
Study: 33681685
Drug: Systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic therapy
Study: 33401223
Drug: Aspirin (AP)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (AP)
Study: 33401223
Drug: Combination (A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination (A + S)
Study: 33692185
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser (LLL, AsGaAl) at a wavelength of 780 nm (Laser XT Therapy, DMC, São Carlos, Brazil)
Study: 36046939
Drug: Medical nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical nutrition therapy (MNT)
Study: 35387739
Drug: Single-dose antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose antibiotic prophylaxis (2 g amoxicillin 1 h before surgery)
Study: 35387739
Drug: Single-dose prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose prophylactic antibiotic (2 g amoxicillin 1 h before surgery) with additional doses after surgery (500 mg amoxicillin, q8h for 5 days)
Study: 35387739
Drug: Post-surgical antibiotics
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-surgical antibiotics alone (500 mg amoxicillin, q8h for 5 days)
Study: 33767791
Drug: Ketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.5 mg/kg body weight)
Study: 33767791
Drug: Nesdonal (3-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nesdonal (3-5 mg/kg body weight)
Study: 616118926
Drug: 20 mm
Normalized name: Adapta-Cap B 20 mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mm diameter implant
Study: 35098466
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg Cd/kg of feed
Study: 35098466
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg Cd/kg of feed
Study: 35098466
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg Cd/kg of feed
Study: 35555782
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D and calcium supplementation (2000 IU/d vitamin D3 and 1500 mg/d calcium)
Study: 39632341
Drug: LEM 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEM 10 mg
Study: 35748777
Drug: LEM 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEM 20 mg
Study: 35748777
Drug: LEM 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEM 30 mg
Study: 35749758
Drug: Zolpidem (ZOL)
DrugBank: Zolpidem (DB00425)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zolpidem (ZOL) 30 mg
Study: 35749758
Drug: Suvoxexant (SUV)
Normalized name: Suvorexant
DrugBank: Suvorexant (DB09034)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Suvoxexant (SUV) 40 mg
Study: 32967921
Drug: Metformin (DM+MF)
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (DM+MF)
Study: 38770009
Drug: Mepolizumab 100
Normalized name: mepolizumab 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab 100 mg subcutaneously every 4 weeks for 52 weeks
Study: 35822924
Drug: Mepolizumab 100
Normalized name: mepolizumab 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab 100 mg subcutaneously
Study: 34455849
Drug: Abbreviated antiplatelet
Normalized name: simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abbreviated antiplatelet therapy (APT) for 5 months in patients with OAC indication; 11 months in patients without OAC indication.
Study: 36002048
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of NL003
Study: 35507141
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline plus oral acetazolamide (5 mg/kg/day)
Study: 35507141
Drug: Half saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half saline plus 75 mEq/L sodium bicarbonate
Study: 34193503
Drug: Daily PEP
Normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily PEP flute usage as add-on to usual care
Study: 33407760
Drug: Regression approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regression approach for personalised treatment recommendation
Study: 34313633
Drug: Enhanced vasodilation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced vasodilation treatment (EVT) based on renin‐angiotensin blockade and/or amlodipine
Study: 34313633
Drug: Reduced vasodilation
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced vasodilation treatment (RVT) based on nonvasodilating β‐blockade (metoprolol)
Study: 33657403
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with rivaroxaban and an antiplatelet agent
Study: 32293463
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal therapy (HFNT) during pulmonary rehabilitation (PR)
Study: 32293463
Drug: Non-high-flow nasal
Normalized name: marine non-gelling gelatin, high MW
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-high-flow nasal therapy (non-HFNT) during pulmonary rehabilitation (PR)
Study: 34906660
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy (ACT) delivered via mobile phone messaging for 14 days, twice daily messages
Study: 33338430
Drug: Multisensory-motor training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multisensory-motor training to distinguish mirror letters (e.g., 'b' vs 'd') for 7.5 hours combined with post-training sleep.
Study: 33047586
Drug: Routine mesoappendixectomy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine mesoappendixectomy, restrictive strategy for abdominal drainage, and postoperative antibiotic prevention (main group)
Study: 32845021
Drug: Multinutrient supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multinutrient supplements (fish oil and multivitamin)
Study: 32845021
Drug: Multinutrient supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multinutrient supplements and food‐related behavioral activation therapy (F‐BA)
Study: 32845021
Drug: Placebos and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebos and food‐related behavioral activation therapy (F‐BA)
Study: 36410405
Drug: Canine-assisted intervention
Normalized name: CanineAid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canine-assisted intervention (CAI) consisting of 35-min weekly sessions over 6 weeks
Study: 34378511
Drug: Saline (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (no treatment)
Study: 32660566
Drug: Long-term (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-term (6 days) supplementation of amaranth concentrate derived dietary NO3- (±400 mg)
Study: 33089386
Drug: Lactic acid
Normalized name: Lactic Acid
DrugBank: Lactic acid (DB04398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactic acid 30% with ferulic peel 12% (combination peel)
Study: 33089386
Drug: Ferulic peel
Normalized name: orange peel extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferulic peel 12% alone (monotherapy)
Study: 32098219
Drug: Acute EGCG
Normalized name: EGCG
DrugBank: Epigallocatechin gallate (DB12116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute EGCG administration (morning and evening in mice)
Study: 36200646
Drug: High‐dose dual‐impregnated
Approvals — FDA: no, EMA: no, PMDA: no
Description: High‐dose dual‐impregnated antibiotic‐loaded cement (DIAC) including gentamicin and clindamycin
Study: 36200646
Drug: Low‐dose single‐impregnated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low‐dose single‐impregnated gentamicin antibiotic‐loaded cement (SIAC)
Study: 32536106
Drug: Nonsplint group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsplint group (oral information about daily activities)
Study: 33675139
Drug: Statistical methods
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statistical methods for estimating treatment effects
Study: 33066334
Drug: Combined nutraceutical
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined nutraceutical containing phytosterols (800 mg) and red yeast rice (5 mg of monacolins), niacin (27 mg), and policosanols (10 mg)
Study: 35554955
Drug: Oral eltrombopag
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral eltrombopag (50 mg daily)
Study: 35554955
Drug: Subcutaneous rhTPO
Normalized name: rhTPO
DrugBank: Recombinant Human Thrombopoietin (DB16364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous rhTPO (15000U daily)
Study: 35970302
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (SOC; salvage chemoimmunotherapy followed by high-dose therapy with autologous stem cell rescue for responders)
Study: 36008120
Drug: 177Lu-PSMA-617 and
Normalized name: 177Lu-PSMA-617
DrugBank: Lutetium Lu-177 vipivotide tetraxetan (DB16778)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 177Lu-PSMA-617 and NOX66 combination treatment
Study: 33279374
Drug: Oral olanzapine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral olanzapine, risperidone, amisulpride, aripiprazole, or perphenazine (Phase 1)
Study: 33279374
Drug: Oral olanzapine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral olanzapine, amisulpride, or clozapine (Phase 2)
Study: 33279374
Drug: Clozapine extended
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clozapine extended treatment or modified electroconvulsive therapy (Phase 3A)
Study: 35640246
Drug: Postoperative mFOLFOX6
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative mFOLFOX6 (12 courses of intravenous oxaliplatin [85 mg/m2] with L-leucovorin [200 mg/m2] followed by 5-fluorouracil [400 mg/m2, bolus and 2400 mg/m2, continuous infusion, repeated every 2 weeks])
Study: 33784467
Drug: VAULT treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAULT treatment with brief utterances (four words or fewer)
Study: 33784467
Drug: VAULT treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAULT treatment with extended utterances (five words or more)
Study: 33784467
Drug: CART analysis
Normalized name: prilocaine
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CART analysis for treatment responders
Study: 33764102
Drug: Intranasal amphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal amphetamine administration
Study: 33589758
Drug: Intensive blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive blood pressure treatment (systolic BP target of 120 mm Hg)
Study: 33589758
Drug: Standard blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard blood pressure treatment (systolic BP target of 140 mm Hg)
Study: 34301646
Drug: Dexamethasone alongside
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone alongside standard antiviral treatment with aciclovir
Study: 34265791
Drug: Methadone (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone (2.5 mg/12 h) in combination with morphine
Study: 32331082
Drug: Lurasidone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone (40 mg/day or 80 mg/day)
Study: 33559971
Drug: Eurycoma longifolia
Normalized name: Eurycoma longifolia root
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eurycoma longifolia 600 mg/day for two weeks
Study: 35661898
Drug: Targeted home
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted home visits by community nurses post treatment administration
Study: 33162329
Drug: BCAA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA supplementation (pre-exercise: 0.084 g kg−1 BW; during exercise: 0.056 g kg−1 h−1)
Study: 33162329
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution (non-caloric)
Study: 36221338
Drug: Phellinus linteus
Normalized name: PHELLINUS LINTEUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phellinus linteus extract 1000 mg per day
Study: 36221338
Drug: Phellinus linteus
Normalized name: PHELLINUS LINTEUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phellinus linteus extract 2000 mg per day
Study: 36221338
Drug: Placebo (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2000 mg of dextrin per day)
Study: 34988780
Drug: Immediate-release formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release formulation
Study: 34561872
Drug: High-volume Foley
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-volume Foley catheter (60 ml) and vaginal misoprostol
Study: 32749459
Drug: Intracoronary administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary administration of allogeneic cardiosphere-derived cells (CDCs)
Study: 33126051
Drug: More precise
Normalized name: Sore No More
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More precise dosing with 0.5 mg acenocoumarol increments
Study: 33126051
Drug: Conventional dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dosing with 1.0 mg acenocoumarol increments
Study: 34417217
Drug: Internet-based cognitive-behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive-behavioural therapy (ICBT)
Study: 35982162
Drug: Vitamin B12
Normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B12 supplementation (1000 µg cyanocobalamin per day for 12 weeks)
Study: 32157328
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch (0 mg)
Study: 36173237
Drug: Bionic Pancreas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bionic Pancreas (BP) with insulin aspart or insulin lispro
Study: 32248163
Drug: Antiseptic solution
Normalized name: ANTISEPTIC SOLUTION
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiseptic solution 'Decasan'; probiotic 'BioGaia ProDentis'; immune modulator 'Imupret'
Study: 36367997
Drug: 12 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 cycles of adjuvant fluorouracil, leucovorin, and oxaliplatin chemotherapy
Study: 36367997
Drug: Exercising ≥
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercising ≥ 9 MET-hours per week after treatment
Study: 33421928
Drug: Ozone therapy
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone therapy (ozonized rectal insufflation and minor auto haemotherapy) along with standard of care (SOC)
Study: 32020853
Drug: A. konjac
Approvals — FDA: no, EMA: no, PMDA: no
Description: A. konjac extract capsules (5 mg glycosylceramides)
Study: 34699271
Drug: Transoral surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transoral surgery (TOS) plus 66 Gy postoperative radiation therapy (RT) and weekly cisplatin
Study: 33843410
Drug: Semi-immersive Virtual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semi-immersive Virtual Reality navigation therapy (vSail-Access®), 30-40 min per day, three times per week for six weeks
Study: 36878996
Drug: N-acetylcysteine (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (1200 mg twice daily)
Study: 33682983
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) 10 mg/kg daily divided into 2 doses every 12 h
Study: 35006266
Drug: Intravenous edaravone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous edaravone
Study: 35006266
Drug: Riluzole only
Normalized name: Riluzole only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riluzole only (standard therapy)
Study: 35749997
Drug: Topical tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical tranexamic acid (TXA) 5 mg/kg
Study: 33954850
Drug: Nonsurgical periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonsurgical periodontal treatment (NSPT) in the +PE+RA group
Study: 35709376
Drug: Budesonide 4
Normalized name: budesonide 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 4 mg suppository
Study: 35709376
Drug: Budesonide 2
Normalized name: budesonide 2 MG/ACTUAT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 2 mg foam
Study: 38172996
Drug: 250 μg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 μg/day B12 supplementation
Study: 33297826
Drug: Complete Decongestive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete Decongestive Therapy (CDT) plus exercises
Study: 33297826
Drug: Intermittent Pneumatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent Pneumatic Compression Therapy (IPCT) plus exercises
Study: 36409969
Drug: CBD oil
Normalized name: MENTHOL, UNSPECIFIED FORM 10 g in 100 g / CAMPHOR (NATURAL) 3 g in 100 g TOPICAL CREAM [ETERNAL SPIRIT BEAUTY PAINLESS WITH CBD OIL 3000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD oil (100 mg/mL, 0.5 mL once daily to 2 mL three times a day)
Study: 36564395
Drug: Rifampin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin (600 mg)
Study: 33166694
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) 800 mg on Day 1 followed by 400 mg once weekly for 3 weeks
Study: 35285904
Drug: 38% hydrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 38% hydrogen peroxide bleaching treatment
Study: 34581025
Drug: AS04-HPV-16/18 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS04-HPV-16/18 vaccine (90% of Arm A and 90% of Arm B girls)
Study: 34581025
Drug: AS04-HPV-16/18 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS04-HPV-16/18 vaccine (90% of Arm B girls)
Study: 34581025
Drug: AS04-HPV-16/18 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS04-HPV-16/18 vaccine (in pooled Arms A/B)
Study: 34581025
Drug: HBV vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBV vaccine (10% of Arm A girls and all boys in Arm B, all participants in Arm C)